Chemotherapy Plus Proton-chemotherapy for Locally Advanced Pancreatic Cancer

This study is currently recruiting participants. (see Contacts and Locations)
Verified May 2015 by Loma Linda University
Information provided by (Responsible Party):
Gary Yang, MD, Loma Linda University Identifier:
First received: February 17, 2012
Last updated: May 11, 2015
Last verified: May 2015

The current trial will provide important data on the recurrence rates and patterns of failure using state of the art target agent, chemotherapy and proton beam technology for patients with Locally Advanced Pancreatic Cancer (LAPC). A median survival of 10 months or greater would be considered evidence of a regimen potentially worthy of further study as a new treatment paradigm in one arm in a future phase III trial.

Condition Intervention Phase
Pancreatic Cancer
Radiation: Proton, Gemcitabine, Erlotinib, Capecitabine
Radiation: Proton Radiation
Phase 2

Study Type: Interventional
Study Design: Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase II Trial of Gemcitabine and Erlotinib (GE) Plus Proton-chemotherapy (PCT) and Capox for Locally Advanced Pancreatic Cancer (LAPC)

Resource links provided by NLM:

Further study details as provided by Loma Linda University:

Primary Outcome Measures:
  • To determine the one-year survival rate [ Time Frame: One year ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • To evaluate the frequency of serious adverse events [ Time Frame: Ongoing ] [ Designated as safety issue: Yes ]

Estimated Enrollment: 43
Study Start Date: December 2011
Estimated Study Completion Date: December 2020
Estimated Primary Completion Date: December 2017 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Proton Radiation Radiation: Proton, Gemcitabine, Erlotinib, Capecitabine

Gemcitabine 1000 mg/m2 iv, days 1, 8, 15, 29, 36 and 43 Erlotinib 100 mg po qd days 1-43 Capecitabine 825mg/m2 po bid M-F, starting on day 1 of proton therapy until proton therapy completed.

Post-proton chemotherapy: To be started in 4 to 6 weeks after completion of proton chemotherapy. Oxaliplatin 130 mg/m2 po bid on days 2 to 15 for 14 days. The CapOx regimen (Capcitabine plus Oxaliplatin) is repeated every 3 weeks for 4 cycles.

Radiation: Proton Radiation


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Histologically or cytologically confirmed unresectable non-metastatic adenocarcinoma of the pancreas
  • AJCC stage I-III with unresectable or borderline unresectable disease as defined by NCCN guidelines
  • Radiological resectability is defined by the following criteria on abdominal imaging:

    1. No evidence of tumor extension to the celiac axis, hepatic artery or superior mesenteric artery.
    2. No evidence of tumor encasement or occlusion of the superior mesenteric vein (SMV) or the SMV/portal vein confluence
    3. No evidence of visceral or peritoneal metastases
  • Borderline and Unresectable cases would be defined as those that do not meet the criteria in section and also show no evidence of distant metastatic or intraperitoneal disease.
  • Eastern Cooperative Oncology Group performance status of ≤ 2
  • Age > 18 years
  • Adequate hematologic reserve, hepatic reserve and renal function
  • WBC > 2,000 cells/mm3
  • ANC > 1,500 cells/mm3
  • Platelets > 100,000 cells/mm3
  • Serum bilirubin ≤ 2.5 mg/dL
  • Serum creatinine ≤ 2 x upper limit of normal (ULN), or creatinine clearance (Ccr) ≥ 30ml/min
  • ALT < 3 times ULN
  • AST < 3 times ULN
  • Albumin > 3.2 g/dl
  • Patient must sign study-specific informed consent
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01683422

Contact: Gary Yang, MD 909-558-4280
Contact: First Call: Proton Referral RN Backup: Sandi Teichman 1 800 776-8667

United States, California
Loma Linda University Medical Center Recruiting
Loma Linda, California, United States, 92354
Contact: Gary Yang, MD    909-558-4280   
Contact: Proton Referral    1 800 496-4966      
Principal Investigator: Gary Yang, MD         
Sponsors and Collaborators
Loma Linda University
Principal Investigator: Gary Yang, MD Loma Linda University
  More Information

No publications provided

Responsible Party: Gary Yang, MD, MD, Principal Investigator, Loma Linda University Identifier: NCT01683422     History of Changes
Other Study ID Numbers: 5110324
Study First Received: February 17, 2012
Last Updated: May 11, 2015
Health Authority: United States: Institutional Review Board

Additional relevant MeSH terms:
Pancreatic Neoplasms
Digestive System Diseases
Digestive System Neoplasms
Endocrine Gland Neoplasms
Endocrine System Diseases
Neoplasms by Site
Pancreatic Diseases
Anti-Infective Agents
Antimetabolites, Antineoplastic
Antineoplastic Agents
Antiviral Agents
Enzyme Inhibitors
Immunologic Factors
Immunosuppressive Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs
Protein Kinase Inhibitors
Radiation-Sensitizing Agents
Therapeutic Uses processed this record on October 07, 2015